Physician profile
Felipe A Navas
NPI 1508889403
$16,489.21
in general payments reported to CMS, 2019-2025
24 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $232 · 2021: $6,337 · 2022: $565 · 2023: $5,964 · 2024: $1,360 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,345 · Food and Beverage: $3,662 · Travel and Lodging: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,345.00 |
| Food and Beverage | $3,662.07 |
| Travel and Lodging | $466.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $6,322.63 | 2021 | |
| Genentech USA, INC. | $5,537.79 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $653.33 | 2022-2025 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $602.05 | 2023-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $600.58 | 2019-2025 | Constellation, Unity |
| Astellas Pharma US INC | $440.71 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $430.83 | 2023-2024 | |
| Allergan, INC. | $248.71 | 2019-2022 | |
| Abbvie INC. | $205.36 | 2022-2024 | |
| Mallinckrodt Enterprises LLC | $148.95 | 2019 | |
| Aerie Pharmaceuticals, INC. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2020 | |
| Amgen INC. | $121.63 | 2024 | Tepezza |
| Optovue, INC. | $120.14 | 2019 | |
| Genentech, INC. | $108.54 | 2025 | Vabysmo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $107.14 | 2022 | |
| Nova Eye, INC. | $105.13 | 2025 | |
| Dutch Ophthalmic, USA | $101.25 | 2019 | |
| Rxsight INC | $101.10 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $92.99 | 2020 | |
| Apellis Pharmaceuticals, INC. | $82.75 | 2023 | Syfovre |
| Alimera Sciences, INC. | $53.88 | 2019-2024 | Yutiq, Iluvien |
| Biogen, INC. | $33.12 | 2023-2024 | Byooviz |
| Bausch & Lomb Americas INC. | $20.60 | 2024 | Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Navas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.